AzTrials
AzTrials

Spinal HypotensionNCT07655245

Caffeine and Prophylactic Noradrenaline Requirement During Cesarean Delivery

A study testing Caffeine (200 mg) in people with Spinal Hypotension and Vasopressor, run by Cairo University at 1 site in Egypt.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Spinal anesthesia is the preferred regional technique in obstetric practice because it provides high maternal satisfaction and eliminates the need for airway manipulation. Despite these advantages, it is frequently complicated by spinal anesthesia-induced hypotension , defined as a reduction in systolic blood pressure… Read more about this study

Who is it for?
Ages 20 to 40 years, women only
Conditions the study is for
Spinal Hypotension, Vasopressor
What is being tested?
Caffeine (200 mg)
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
62 participants
Where
1 siteEgypt
Study dates
16 Jun 2026to 19 Sep 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 40 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Full-term singleton pregnant (>37 weeks)
  • ASA II
  • undergoing elective cesarean section.

Who cannot join

  • Patient refusal
  • SBP < 100 mmHg
  • Allergy to local anesthetics or caffeine
  • Coagulopathy (INR>1.4 or platelets <75.000)
  • Preeclampsia

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Mina Adolf Helmy, MD contact

01275716942

minaadolf1988@cu.edu.eg

Egypt1 site
  • Cairo University Hospitals

    Cairo

    Mina Adolf Helmy, MD, 01275716942, minaadolf1988@cu.edu.eg

Other trials in Egypt

About this study

Official title: Effect of Preoperative Oral Caffeine on Prophylactic Noradrenaline Requirement During Cesarean Delivery: A Double-blind Placebo-controlled Trial

Spinal anesthesia is the preferred regional technique in obstetric practice because it provides high maternal satisfaction and eliminates the need for airway manipulation. Despite these advantages, it is frequently complicated by spinal anesthesia-induced hypotension , defined as a reduction in systolic blood pressure of more than 20% from baseline or an absolute SBP below 100 mmHg. Spinal hypotension can have serious consequences, including maternal hypoperfusion that may lead to neurological or renal dysfunction, as well as fetal acidosis and bradycardia, which can compromise neonatal outcomes. The present study aims to evaluate the effect of preoperative caffeine administration on noradrenaline requirements during spinal anesthesia in obstetric patients. Specifically, the objectives are to compare noradrenaline requirements between the study groups and to assess the incidence of hypotension in both groups.

Read the detailed description

Spinal anesthesia is considered the technique of choice in obstetric practice because it provides excellent maternal comfort and avoids the risks associated with airway manipulation during general anesthesia. Nevertheless, its use is often complicated by a significant drop in blood pressure, which can reduce blood flow to vital organs and impair maternal brain and kidney function. More importantly, decreased uteroplacental perfusion may compromise fetal oxygenation, leading to acidosis and slowing of the heart rate, both of which can negatively affect neonatal outcomes. These risks make it essential to explore preventive strategies that can stabilize blood pressure during spinal anesthesia. Caffeine, a widely available and inexpensive stimulant, enhances sympathetic nervous system activity and may counteract the vasodilation that contributes to low blood pressure. This study therefore investigates whether giving caffeine before anesthesia can reduce the need for noradrenaline, a commonly used vasopressor, and whether it can lower the incidence of hypotension. By examining these outcomes, the research aims to determine if caffeine could serve as a simple intervention to improve both maternal safety and neonatal wellbeing.

Being tested
Caffeine (200 mg), Placebo
Keywords
Spinal anesthesia induced hypotension, Vasopressor, Caffeine

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Caffeine (200 mg)Drug

    Patients will receive 200 mg oral caffeine 30 minutes before spinal anesthesia

  • PlaceboDrug

    Patient will receive placebo capsule

Study groups in NCT07655245
Study groupRoleWhat they receive
CaffeineActive comparator30 minutes before spinal anesthesia in the preoperative area, the patient will receive 200 mg caffeine capsule
Receives: Drug: Caffeine (200 mg)
ControlPlacebo comparator30 minutes before spinal anesthesia in the preoperative area, the patient will receive placebo
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Average noradrenaline requirement

    The total noradrenaline administered as an infusion plus boluses divided by patient weight and infusion time.

    Measured: After spinal anesthesia till delivery

Secondary outcomes (3)
  1. Incidence of spinal hypotension

    Reduction of systolic blood pressure more than 20% of baseline

    Measured: After spinal anesthesia till end of delivery

  2. Time to first hypotensive episode

    Time to develop the first hypotensive episode in minutes

    Measured: After spinal anesthesia till delivery of the baby

  3. APGAR score

    Assessment of APGAR score of neonates

    Measured: at 10 minutes of delivery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jun 2026
  2. Study start16 Jun 2026 (estimated)
  3. Primary completion16 Sep 2026 (estimated)
  4. Study completion19 Sep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
62 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07655245
Sponsor's protocol ID
Caffeine and noradrenaline
Status last verified
Jun 2026
First submitted
12 Jun 2026
Last updated
17 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: At present, we have not finalized a plan for sharing individual participant data. Decisions regarding data sharing will depend on factors such as ethical approval, participant consent, and institutional policies. If sharing becomes feasible, de-identified data may be made available upon reasonable request following appropriate review.

Publications

  • Helmy MA, Helmy KA, Darandly WME, Awad HH, Morsy F, Kaddah RA, Shamma MA, Milad LM. Prediction of spinal anesthesia-induced hypotension during cesarean delivery: a narrative review. J Anesth Analg Crit Care. 2026 Apr 11;6(1):61. doi: 10.1186/s44158-026-00382-y.

    PubMed 41964042
  • Helmy MA, Helmy KA, Kaddah RA, Shamma MA, Ali MA, Milad LM. Femoral artery Doppler as a novel predictor of spinal hypotension in elective cesarean delivery cases: a prospective observational study. Int J Obstet Anesth. 2025 Aug;63:104706. doi: 10.1016/j.ijoa.2025.104706. Epub 2025 Jun 18.

    PubMed 40550198
  • Helmy MA, Helmy KA, Zaki RM, Khatab SA, Embaby SA, Kaddah RA, Shamma MA, Milad LM. Caffeine before cesarean delivery: a novel preventive strategy against spinal hypotension, a double blind placebo-controlled trial. J Anesth Analg Crit Care. 2026 Jan 15;6(1):12. doi: 10.1186/s44158-025-00333-z.

    PubMed 41535923

Questions about this trial

What is this clinical trial studying?

A study testing Caffeine (200 mg) in people with Spinal Hypotension and Vasopressor, run by Cairo University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 17 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Mina Adolf Helmy, MD (01275716942, minaadolf1988@cu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Average noradrenaline requirement (time frame: After spinal anesthesia till delivery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07655245, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in